TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00811993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
Study: NCT01649297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (high dose qd)
Description: Patients receive Empagliflozin high dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (high dose bid)
Description: Patients receive Empagliflozin high dose split twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive placebo matching Empagliflozin (high dose qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (low dose bid)
Description: Patients receive Empagliflozin low dose split twice daily
Study: NCT01858064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Description: Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
Study: NCT02298855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualised follow-up
Description: Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
Study: NCT01839383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different dialysate calcium concentration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different dialysate calcium concentration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different dialysate calcium concentration
Study: NCT04420897

Intervention type: PROCEDURE
Intervention: Arterial blood gas samples
Description: Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.

Intervention type: PROCEDURE
Intervention: Arterial blood gas samples
Description: Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.

Intervention type: PROCEDURE
Intervention: Arterial blood gas samples
Description: Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
Study: NCT01202409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
Study: NCT00858247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
Study: NCT00951964

Intervention type: DRUG
Group type: OTHER
Intervention: Polyphenon E before Placebo
Description: patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo before treatment
Description: patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
Study: NCT01061853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOPICAL SIROLIMUS (RAPAMUNE*)
Description: APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOPICAL BETAMETHASONE 0.05%
Description: APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
Study: NCT01661530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E enhanced soup
Description: vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-enhanced soups
Description: Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
Study: NCT00141713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
Study: NCT02648113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion
Description: Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Description: transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood transfusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood transfusion
Study: NCT02651883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening invitation (with education)
Description: The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening invitation (with education)
Description: The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-collection for HPV testing
Description: Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
Study: NCT00006341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant
Description: A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
Study: NCT04051099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)
Description: bilateral superficial cervical plexus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus propofol infusion
Description: Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus propofol infusion
Description: Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltraion analgesia
Description: local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltraion analgesia
Description: local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with endotracheal tube
Description: Induction with Propofol and intubation with cisatracurium
Study: NCT02009059

Intervention type: DEVICE
Intervention: Non-invasive temperature in hypothermia
Description: accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
Study: NCT03806023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand movements (signals from thumb muscle) triggered PNS and TMS
Description: PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study: NCT02176083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message management prompts
Study: NCT02176460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5mg twice daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice daily
Study: NCT04267185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Together for PwMS and their CGs (PAT-MS)
Description: A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
Study: NCT02615392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park Prescription
Description: Please refer to the information included in the arm description.
Study: NCT03213197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR video
Description: Patient watches a short CPR video
Study: NCT02912455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: canagliflozin
Description: encapsulated (gelatin capsule).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for canagliflozin)
Description: encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
Study: NCT01934127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789868A
Description: One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
Study: NCT01542905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Korean Red Ginseng Capsule (1g/day) for 8 Weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule (1g/day) for 8 Weeks
Study: NCT01982838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural de novo
Description: Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
Study: NCT03096197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Walking
Description: Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Walking
Description: Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Lumbosacral Stimulation (TLS)
Description: EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
Study: NCT01746108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: 1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
Study: NCT01982838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
Study: NCT03982940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGP+ Stent Graft System as bridging stent
Description: BGP+ Stent Graft System as bridging stent
Study: NCT00395642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kronos LV-T, Lumax HF-T
Description: Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
Study: NCT00096993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as a single-use formulation for infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was provided as a solution for infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was provided as a solution for infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab was provided as a single-use formulation for infusion.
Study: NCT02164032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal insulin administration
Description: intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Dilution Buffer (Novo Nordisk)
Description: intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1H magnetic resonance spectroscopy
Description: 1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1H magnetic resonance spectroscopy
Description: 1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
Study: NCT03092336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: electrical stimulation training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: strength training group
Study: NCT00886925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Day 0: 400-600 ml. Day 2: 200-400 ml.
Study: NCT01291134

Intervention type: BIOLOGICAL
Intervention: PureGen Osteoprogenitor Cell Allograft
Description: PureGen Osteoprogenitor Cell Allograft.
Study: NCT01746108

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
Study: NCT01328808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/APAP
Description: In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute
Study: NCT00772655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab
Description: A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
Study: NCT00563745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine program
Description: One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
Study: NCT02604485

Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 1
Description: XOMA 358 single dose level A administered by an intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 2
Description: XOMA 358 single dose level B administered by an intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 3
Description: XOMA 358 single dose level C administered by an intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 4
Description: XOMA 358 single dose level D administered by an intravenous infusion
Study: NCT04208347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 250mg
Description: Apatinib 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Oxaliplatin
Description: S-1, Oxaliplatin, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Oxaliplatin
Description: S-1, Oxaliplatin, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1, Oxaliplatin
Description: S-1, Oxaliplatin, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 500mg
Description: Apatinib 500mg